TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Valneva ( (VALN) ) is now available.
On November 26, 2025, Valneva SE announced its financial results for the first nine months of 2025, reporting total revenues of €127.0 million, an 8.9% increase from the previous year. Despite a net loss of €65.2 million, the company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Valneva’s Lyme disease vaccine candidate, VLA15, is progressing well in its Phase 3 study, with results expected in 2026. The company also highlighted the growth in sales of its Japanese encephalitis vaccine and the launch of its chikungunya vaccine, IXCHIQ®, despite regulatory challenges in the U.S.
The most recent analyst rating on (VALN) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score is primarily influenced by financial performance and technical analysis. The company’s financial challenges, including high leverage and negative profitability, weigh heavily on the score. Technical indicators suggest bearish momentum, further impacting the score. Valuation concerns, with a negative P/E ratio, also contribute to the lower score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases. The company offers a range of travel vaccines, including IXIARO®/JESPECT® for Japanese encephalitis, DUKORAL® for cholera and ETEC-diarrhea, and IXCHIQ® for chikungunya. Valneva operates in various markets, distributing its own products and certain third-party products through its marketing and sales infrastructure.
Average Trading Volume: 47,239
Technical Sentiment Signal: Hold
Current Market Cap: $753.6M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.